𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Gene therapy for human prostate cancer. Translational research in the hormone refractory dunning prostate cancer model

✍ Scribed by Michael A. Carducci; Sujatha R. Ayyagari; Martin G. Sanda; Jonathan W. Simons

Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
833 KB
Volume
75
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Human osteocalcin: a strong promoter for
Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer
✍ Helen O. McCarthy; Jonathan A. Coulter; Jenny Worthington; Tracy Robson; David G πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 818 KB

## Abstract ## Background Gene therapy has been identified as a promising treatment strategy for hormone refractory prostate cancer (HRPC). We report, for the first time, the use of the human osteocalcin (hOC) promoter to control inducible nitric oxide synthase (iNOS) transgene expression in HRPC.

Gene-directed enzyme prodrug therapy for
Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease
✍ Rosetta Martiniello-Wilks; Allison Dane; Dale J. Voeks; Geetha Jeyakumar; Elin M πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 310 KB πŸ‘ 1 views

## Abstract ## Background Gene‐directed enzyme prodrug therapy (GDEPT) based on the __E. coli__ enzyme purine nucleoside phosphorylase (PNP) represents a new approach for treating slow growing tumours like prostate cancer (PCa). Expressed enzyme converts a systemically administered prodrug, fludar

Amplification of the androgen receptor g
Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer
✍ Koivisto, Pasi A.; Rantala, Immo πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 257 KB πŸ‘ 2 views

p53 protein expression of 30 hormone-refractory locally recurrent prostate cancers was compared with their matched untreated primary tumour specimens. In addition, androgen receptor (AR) gene amplification and p53 protein immunostaining were compared. p53 positivity increased during hormonal therapy